产品
编 号：F378141
分子式：C13H14Cl2O3
分子量：289.15
分子式：C13H14Cl2O3
分子量：289.15
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
400
In-stock
500mg
1000
In-stock
结构图
CAS No: 52214-84-3
产品详情
生物活性：
Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias.
体内研究：
Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of ?choline-deficient (MCD) diet-fed mice.Animal Model:C57BL/6 mice (six-week-old males)
Dosage:10 mg/kg
Administration:Oral administration; 10 mg/kg/day; 3 days
Result:Decreased MCD diet-resulted hepatic steatosis and hepatic necro-inflammation in mice.
体外研究：
Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells.In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid.Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%.Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents?in HepG2 cells.Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells.
Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha. Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias.
体内研究：
Ciprofibrate (oral administration; 10 mg/kg/day; 3 days) does not result in any significant effects on body weight or absolute liver weight for MCD diet-fed mice. Ciprofibrate improves hepatic steatosis and reduced hepatic necro-inflammation in MCD diet-fed mice. It also reduced hepatic cytokine protein and mRNA levels (MCP-1, TNFα and IL-6) as compared to those of ?choline-deficient (MCD) diet-fed mice.Animal Model:C57BL/6 mice (six-week-old males)
Dosage:10 mg/kg
Administration:Oral administration; 10 mg/kg/day; 3 days
Result:Decreased MCD diet-resulted hepatic steatosis and hepatic necro-inflammation in mice.
体外研究：
Ciprofibrate (500 μM; 4 hours) increases the PPARa phosphorylation level in rat Fao cells.In a LucLite assay, Ciprofibrate (10-100μM; 24 hours) induces PPARR activation by existing increased LUC activities in the rat liver H4IIEC3 cells transfected with PPRE-AB LUC reporter gene plasmid.Ciprofibrate (10-100 μM; 24 hours) is not cytotoxic for HepG2 cells, and the cell viability is 99.7%.Ciprofibrate (100 μM; 24 hours) also abolishes FFAs mixture-induced lipid deposition and decreases FFAs mixture-increased TG contents?in HepG2 cells.Ciprofibrate (100 μM; 24 hours) almost entirely eliminates the FFAs mixture-induced inflammatory cytokines overproduction, including MCP-1, TNF-α, and IL-6 in HepG2 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备